METHODS AND COMPOSITIONS FOR MODULATING IMMUNOLOGICAL TOLERANCE

• US 20110150845A1
• Filed: 05/01/2009
• Published: 06/23/2011
• Est. Priority Date: 05/02/2008
• Status: Abandoned Application

• Current Assignee: Dana-Farber Cancer Institute, Massachusetts Institute of Technology, The General Hospital Corporation (Mass General Brigham, Inc.)
• Original Assignee: Dana-Farber Cancer Institute, Massachusetts Institute of Technology, The General Hospital Corporation (Mass General Brigham, Inc.)
• Inventors: Turley, Shannon J., Yarmush, Martin Leon, Parekkadan, Biju
• Application Number:
  US12/990,331
• Publication Number:
  US 20110150845A1
• Time in Patent Office: Days
• US Class Current: 424/93.7
• CPC Class Codes: A61K 2035/122 for inducing tolerance or supression of immune responses
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: A61K 39/0008 Antigens related to auto-immune diseases; Preparations to induce self-tolerance
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: C12N 5/0663 Bone marrow mesenchymal stem cells (BM-MSC)

Abstract

The invention provides compositions and methods for modulating immune responses using mesenchymal stem cells. The invention further provides methods for inducing tolerance to self antigens using mesenchymal stem cells.

Claims

1. A method for preparing an isolated mesenchymal stem cell population having a defined antigen expression profile comprising determining an antigen expression profile in an isolated mesenchymal stem cell population, and

physically separating the isolated mesenchymal stem cell population based on antigen expression to generate one or more isolated mesenchymal stem cell populations having defined antigen expression profile.

2. The method of claim 1, wherein the antigen expression profile is a peripheral tissue antigen expression profile.

3. The method of claim 1, wherein the antigen expression profile is an antigen expression profile for a single antigen.

4. The method of claim 1, wherein the antigen expression profile is an antigen expression profile for multiple antigens.

5. The method of claim 1, wherein the isolated mesenchymal stem cell population is physically separated based on type of antigen expression.

6. The method of claim 1, wherein the isolated mesenchymal stem cell population is physically separated based on type and level of antigen expression.

7. The method of claim 1, wherein the isolated mesenchymal stem cell population is a bone marrow mesenchymal stem cell population.

11. An isolated mesenchymal stem cell population generated according to claim 1.

15. A method for treating a subject having or at risk of developing an autoimmune disease comprising

administering to a subject in need thereof an isolated mesenchymal stem cell population prepared according to the method of claim 1 in an effective amount to treat the subject.

19. A method for modulating an immune response comprising

administering to a subject in need thereof an isolated mesenchymal stem cell population prepared according to the method of claim 1 in an effective amount to modulate an immune response.

8. A method for preparing a mesenchymal stem cell having a defined antigen profile comprising

expressing an exogenous nucleic acid comprising a peripheral tissue antigen in a mesenchymal stem cell.

9. (canceled)

10. An isolated mesenchymal stem cell population having a defined antigen expression profile.

12. A mesenchymal stem cell bank comprising

a plurality of isolated mesenchymal stem cell populations of claim 10.

13. (canceled)

14. A method for treating a subject having or at risk of developing an autoimmune disease comprising

administering to a subject in need thereof an isolated mesenchymal stem cell population having a defined antigen expression profile in an effective amount to treat the subject.

16-17. -17. (canceled)

18. A method for modulating an immune response comprising

administering to a subject in need thereof an isolated mesenchymal stem cell population having a defined antigen expression profile in an effective amount to treat the subject.

20-22. -22. (canceled)

23. A method for treating a subject having or at risk of developing an autoimmune disease comprising

administering to a subject in need thereof a mesenchymal stem cell lysate lipophilic fraction in an effective amount to treat the subject.

24. A method for treating a subject having or at risk of developing an autoimmune disease comprising

administering to a subject in need thereof a mesenchymal stem cell conditioned media lipophilic fraction in an effective amount to treat the subject.

25-26. -26. (canceled)

27. A method for preparing an MSC antigen presenting cell comprising

in vitro contacting a naï

ve antigen presenting cell with a mesenchymal stem cell lysate or conditioned media, and

allowing sufficient time for the naive antigen presenting cell to express on its surface an antigen or fragment thereof from the mesenchymal stem cell lysate or conditioned media, thereby generating an MSC antigen presenting cell.

39. A method for modulating an immune response comprising

administering to a subject in need thereof an MSC antigen presenting cell prepared according to the method of claim 27 in an effective amount to modulate an immune response.

28-38. -38. (canceled)

40-41. -41. (canceled)

42. A method for identifying a candidate mesenchymal stem cell comprising

contacting a mesenchymal stem cell with an antigen-specific activated immune cell, and

measuring antigen-specific activity of the antigen-specific activated immune cell prior to and after contact with the mesenchymal stem cell,

wherein a reduction in antigen-specific activity as a result of contact with the mesenchymal stem cell identifies a candidate mesenchymal stem cell.

43-44. -44. (canceled)